This study highlights that "typical" PV branching pattern is not a common finding. That 25.6% of the patients present at least 1 accessory PV needs to be kept in careful consideration when planning and performing transcatheter AF ablation. In addition, not only LA volume, but also each PV ostia and LA appendage are significantly enlarged in patients with persistent compared to paroxysmal AF.

the lesions. The two systems did not differ statistically for correlation with the final histology (S1 k = 0.94 ± 0.06; S2 k = 0.92 ± 0.08) and underestimation of B3 lesions or in situ (S1 4.5 %; S2 4.3 %). Sensitivity, specificity, PPV, NPV, diagnostic accuracy of S1 and S2 were also not statistically different. The systems differed only in sampling time (S1 80; S2 63 s), but not in total procedure time. Conclusions Our study confirms the effectiveness of VABB in the assessment of microcalcifications and highlights the lack of significant differences between the two systems in terms of diagnostic performance.

Key Clinical MessageMalignant pleural mesothelioma (MPM) is a rare neoplasm, generally caused by asbestos exposure. This case details how a patient treated with nintedanib during the LUME‐Meso study was rechallenged with nintedanib. The findings highlight the benefit of nintedanib rechallenge and the potential use of continuous anti‐angiogenic therapy in MPM treatment.

No abstract

Malignant pleural mesothelioma (MPM) is a rare tumor that originates in the lung pleura; it commonly results from previous asbestos exposure that occurred between 20 and 50 years prior to disease onset, and its incidence is increasing worldwide. Symptoms commonly related to MPM include chest pain. The causes of the pain are multifactorial: it may be due to tumor infiltration of the ribs of the nerve roots, intercostal nerves, chest wall, or, in some cases, from tumor invasion of the neurovascular bundle. Treatment of chest pain makes use of medical therapy, surgical and radiotherapy approaches.